13F Holdings
中文EN

PVLA PALVELLA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1583648 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-113.9%
TTM EPS YoY-120.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-63.4%
ROA-49.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.3%
Debt / equity0.00x
Current ratio16.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-20.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$42.81M$25.90M$31.42M
R&D expense$22.84M$8.15M$8.79M$52.98M$66.66M
SG&A expense$15.76M$5.94M$3.08M$16.39M$16.59M
Operating income-$38.60M-$14.10M-$11.87M-$43.47M-$51.83M
Interest expense$0$430,000$0——
Pretax income-$41.72M-$17.43M$18.69M-$33.28M-$45.74M
Income tax$0$0$0$0$0
Net income-$41.72M-$17.43M$18.69M-$33.28M-$45.74M
EBITDA——-$9.96M-$40.70M-$49.37M
EPS (basic)-3.71-7.832.19-0.45-0.71
EPS (diluted)-3.71-7.832.17—-0.71
Weighted avg. shares (diluted)11.25M2.23M1.79M—64.55M
Banking
Net interest income$2.59M$642,000———
Balance sheet
Cash & equivalents$57.98M$83.60M$7.35M$38.63M$117.76M
Short-term investments$0—$8.97M$20.53M$0
Receivables$0$358,000$0$5.81M$3.31M
Current assets$58.99M$88.23M$7.55M$73.42M$127.62M
PP&E, net——$0$16.99M$19.12M
Total assets$59.56M$88.23M$7.55M$95.49M$153.56M
Current liabilities$11.34M$12.04M$2.36M$36.58M$50.56M
Total liabilities$31.58M$25.63M$11.43M$67.56M$102.81M
Shareholders' equity$27.98M$62.61M-$74.48M-$93.78M$50.76M
Shares outstanding12.38M11.01M1.77M74.52M72.22M
Cash flow statement
Operating cash flow-$25.01M-$10.84M-$13.70M-$59.93M-$7.66M
Capital expenditure——$171,000$1.04M$949,000
Free cash flow——-$13.87M-$60.97M-$8.61M
Investing cash flow——$12.00M-$21.24M-$949,000
Financing cash flow-$660,000$87.09M$5.00M$7.21M$59.13M
Depreciation & amortization——$1.90M$2.77M$2.46M
Stock-based compensation$6.40M$830,000$603,000$4.40M$5.21M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.